News for Immuron Limited (IMC.AX)

Shares of Interactive Brokers Group, Inc. IBKR rose sharply in pre-market trading after the company posted better-than-expected second-quarter results after Thu...

Record global sales of AUD$7.3 million, exceeding projections with 49% YoY growth Strong North American performance with 76% YoY growth to AUD$2.0 milli

Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sa

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)’s share was trading at $2.14 as of 2nd June. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. Abcellera is approaching a potential inflection point […]

Immuron (IMRN) projects over A$7 million in sales for the current financial year, a significant rise from last year's A$4.9 million. Topline results of

Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan®

Immuron Limited (IMRN) records highest sales in history for Travelan®, exceeding AUD$5.3 million YTD, marking a 46% increase year-over-year. Strong North A

Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2

**media[592095,592096]**

**media[557764,557765]**

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; IMRN), an Australian based and globally integrated biopharmaceutical comp

**media[544182]**

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

**media[517758,517759]**

Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeut

Immuron Ltd has presented a Clinical Study Report to the US Food and Drug Administration following its Phase 2 clinical trial

**media[480648]**

MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore w